

European
Iron
Academy

2nd European Iron Academy
26–27 March 2015, Paris, France

Welcome from the Chairs

Dear Colleagues,

It is our great pleasure to invite you to the **2nd European Iron Academy**.

Now in its second year, the European Iron Academy brings together a range of specialists with an interest in iron deficiency (ID) and ID anaemia (IDA), including haematologists, nephrologists, cardiologists, gastroenterologists, gynaecologists, internal medicine experts, surgeons and anaesthesiologists, as well as general practitioners and hospital pharmacists.



Prof. Patrice Cacoub



Dr. Satish Keshav

The key scientific learning objectives of the European Iron Academy are to:

- Increase awareness about the prevalence of ID(A) in different disease areas and its clinical, social and economic consequences
- Provide an update on the latest clinical developments relating to the management of ID(A) and review the treatment options/share practical experience of managing ID(A) in different disease areas in different countries
- Discuss the challenges relating to diagnosis of ID(A) in different disease areas

The programme will consist of plenary presentations and a series of interactive breakout sessions, which will provide an excellent opportunity to discuss hot topics in ID(A) in smaller groups.

The European Iron Academy 2015 is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The European Iron Academy 2015 is designated for a maximum of 6 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

We hope that you will enjoy what we are sure will be a stimulating and inspiring two days with us.

A handwritten signature in black ink, appearing to be 'P. Cacoub'.

Prof. Patrice Cacoub, Co-Chair

Department of Internal Medicine and Clinical Immunology, Hôpital la Pitié Salpêtrière, Paris, France

A handwritten signature in black ink, appearing to be 'S. Keshav'.

Dr Satish Keshav, Co-Chair

Gastroenterology Unit, John Radcliffe Hospital, Oxford, United Kingdom

Contents

[Agenda](#)

[Steering committee biographies](#)

[Faculty biographies](#)

[Plenary session: Day 1](#)

[Breakout sessions: Days 1 and 2](#)

[Plenary session: Day 2](#)

Agenda

Thursday 26th March 2015

TIME	TOPIC	SPEAKER(S)
08:00 onwards	Registration	
11:00 – 12:15	Buffet lunch	
12:15 – 14:45	Plenary Session	
12:15 – 12:25	<ul style="list-style-type: none"> Welcome & introduction 	P. Cacoub and S. Keshav
12:25 – 13:00	<ul style="list-style-type: none"> Global burden of anaemia and ID(A) <ul style="list-style-type: none"> - Epidemiology (global prevalence and trends) - Disease burden in specific populations - Aetiology of ID(A) – the global picture Physical symptoms and diagnosis 	N. Kassebaum
		P. Cacoub
13:00 – 13:25	<ul style="list-style-type: none"> Introduction to iron metabolism and clinical picture of ID(A) 	I. Macdougall
13:25 – 13:40	<ul style="list-style-type: none"> Panel discussion / Q&A 	
13:40 – 14:30	<ul style="list-style-type: none"> New data in iron trials – what does this mean for patients? 	S. Anker (moderator)
	<ul style="list-style-type: none"> - Pregnancy 	C. Breymann
	<ul style="list-style-type: none"> - Chronic heart failure (CHF) 	P. Ponikowski
	<ul style="list-style-type: none"> - Chronic kidney disease (CKD) 	I. Macdougall
14:30 – 14:45	<ul style="list-style-type: none"> Panel discussion / Q&A 	
14:45 – 15:15	Coffee Break	
15:15 – 18:00	Interactive Breakout Sessions (1 & 2)	
15:15 – 16:30	<ul style="list-style-type: none"> Cardiology <ul style="list-style-type: none"> - Epidemiology of ID(A) in patients with HF - Key data for IV iron in patients with HF - Interactive case studies 	S. Anker and D. van Veldhuisen
	<ul style="list-style-type: none"> Gastroenterology <ul style="list-style-type: none"> - Pathogenesis of ID in gastrointestinal disorders (IBD, Crohn's disease, coeliac disease) and impact on clinical outcome / patient QoL - Overview of diagnostic guidelines - Interactive case studies 	S. Keshav and L. Peyrin-Biroulet
	<ul style="list-style-type: none"> ID in surgery <ul style="list-style-type: none"> - Perioperative management of ID(A) - Importance of patient blood management - Clinical cases to discuss management of ID(A) in different types of surgery 	S. Lasocki and T. Richards

15:15 – 16:30	<ul style="list-style-type: none"> • Nephrology <ul style="list-style-type: none"> - Pathogenesis of ID(A) in CKD patients - Diagnostic challenges in CKD – which markers to measure? - Interactive case studies 	J. Małyszko and A. Stack
15:15 – 16:30	<ul style="list-style-type: none"> • Pharmacoeconomics of iron therapy <ul style="list-style-type: none"> - Cost to society: what is the true impact of ID? - Benefits of treatment (country-specific case studies) 	L. Mantovani and P. Blank
16:30 – 16:45	Delegates rotate to next parallel session	
16:45 – 18:00	<ul style="list-style-type: none"> • Cardiology/renal <ul style="list-style-type: none"> - Impact of ID(A) in patients with cardio-renal anaemia/ID syndrome - Clinical data for iron therapy in heart failure or CKD - Interactive case studies (diagnosis/management of ID in patients with CKD and heart failure) 	C. Gaillard and P. Ponikowski
16:45 – 18:00	<ul style="list-style-type: none"> • Haematology and oncology <ul style="list-style-type: none"> - Diagnosis/management of ID in cancer patients - Patient blood management / transfusion avoidance - Interactive case studies 	N. Kassebaum and Y. Beguin
16:45 – 18:00	<ul style="list-style-type: none"> • ID in the elderly <ul style="list-style-type: none"> - Pathophysiology of ID(A) in the elderly and impact on health or wellbeing - Challenges of diagnosis - Interactive case studies to discuss diagnosis/management of ID in specific patient populations 	P. Cacoub and P. Chassagne
16:45 – 18:00	<ul style="list-style-type: none"> • Optimal dosing and monitoring of IV iron therapy <ul style="list-style-type: none"> - Overview of available data for IV iron therapy (including children, pregnant women) - Guidelines for monitoring iron parameters in patients receiving IV therapy 	I. Macdougall and C. Gasche
16:45 – 18:00	<ul style="list-style-type: none"> • Postpartum and heavy menstrual bleeding <ul style="list-style-type: none"> - Pathogenesis of ID(A) in women - Signs/symptoms and diagnostic work-up of different patient types - Interactive case studies 	C. Breymann and L. Bahamondes
19:00	Meet in the lobby for transfer to dinner	
19:30 – 22:00	Dinner	

Friday 27th March 2015

TIME	TOPIC	SPEAKER(S)
08:00 – 11:00	Interactive Breakout Sessions (3 & 4)*	
08:00 – 09:15	• Cardiology*	S. Anker and D. van Veldhuisen
08:00 – 09:15	• Gastroenterology*	L. Peyrin-Biroulet and S. Keshav
08:00 – 09:15	• Haematology and oncology*	N. Kassebaum and Y. Beguin
08:00 – 09:15	• Nephrology*	J. Małyszko and A. Stack
08:00 – 09:15	• Pharmacoeconomics of iron therapy*	L. Mantovani and P. Blank
09:15 – 09:45	Coffee break / delegates rotate to next parallel session	
09:45 – 11:00	• Cardiology/renal*	C. Gaillard and P. Ponikowski
09:45 – 11:00	• ID in the elderly*	P. Cacoub and P. Chassagne
09:45 – 11:00	• ID in surgery*	S. Lasocki and T. Richards
09:45 – 11:00	• Optimal dosing and monitoring of IV iron therapy*	C. Gasche and I. Macdougall
09:45 – 11:00	• Postpartum and heavy menstrual bleeding*	C. Breymann and L. Bahamondes
11:00 – 11.15	Delegates move to plenary room	
11:15 – 12:45	Plenary Session	
11:15 – 11:30	• Health economics and ID	P. Blank
11:30 – 11:50	• Monitoring patients and maintenance therapy	C. Gasche
11:50 – 12:10	• IV iron preparations and safety	I. Macdougall
12:10 – 12:40	Panel discussion and review of meeting highlights	S. Keshav (moderator)
12:40 – 12:45	Meeting summary and close	
From 12:45	Buffet lunch and departures	

*Breakout sessions on Day 2 are a repeat of those on Day 1. Participants will attend a total of four different breakout sessions (two on Day 1 and two on Day 2), chosen from the ten sessions available.

CHF, chronic heart failure; CKD, chronic kidney disease; HF, heart failure; IBD, inflammatory bowel disease; IV, intravenous; ID(A), iron deficiency (anaemia); Q&A, question and answer; QoL, quality of life.

Steering Committee Biographies



Satish Keshav (Co-chair)

Satish Keshav is Consultant Physician in Gastroenterology and Honorary Senior Lecturer, specialising in inflammatory bowel disease, at the John Radcliffe Hospital, Oxford, United Kingdom.

Dr Keshav's research encompasses investigation of gastrointestinal immunity and inflammation as well as clinical studies and trials. His main interest is in understanding the mechanisms of organ-specific immunity and inflammation in the gastrointestinal tract. In particular, Dr Keshav is interested in determining the role of specialised epithelial cells, which maintain host defence and mediate between extrinsic microorganisms and the innate and adaptive immune systems. He also has an interest in, and has presented widely on, iron deficiency and anaemia in the context of gastrointestinal medicine.

Dr Keshav will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Welcome and introduction](#)
- [Gastroenterology breakout session](#)
- [Panel discussion and review of meeting highlights](#)

[Back to contents](#)

Steering Committee Biographies



Patrice Cacoub (Co-Chair)

Patrice Cacoub is Professor of Internal Medicine at the Pierre and Marie Curie University and Head of the Department of Internal Medicine, La Pitié-Salpêtrière Hospital, Paris, France.

During his career, Professor Cacoub has conducted research on autoimmune diseases, hepatitis C (HCV) and B (HBV) virus, human immunodeficiency virus (HIV), peripheral neuropathies, anaemia and vascular medicine. He has also published on the importance of iron management in internal medicine, and has authored more than 550 research publications, 52 books and 120 Continuing Medical Education publications in these fields.

Professor Cacoub has been involved in the development of a number of national and international guidelines and clinical trials. He has also been involved in initiatives to improve clinical care, particularly in HCV treatment, autoimmune and autoinflammatory diseases, co-infection with HCV and HIV, and peripheral arterial disease.

Professor Cacoub will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Welcome and introduction](#)
- [Physical symptoms and diagnosis](#)
- [ID in the elderly](#)
- [Meeting summary and close](#)

[Back to contents](#)

Steering Committee Biographies



Stefan Anker

Stefan Anker is Professor of Innovative Clinical Trials with a focus on Cardiology and Cachexia Research at the University Medical Centre Göttingen (UMG) in Göttingen, Germany.

Professor Anker's main research activity is in clinical trials, in particular those on the pathophysiology of acute and chronic heart failure. His research interests also include the pathophysiology of symptom generation and cardiac dysfunction in cancer, biomarker research in acute and chronic heart failure, sarcopaenia, and anaemia/iron deficiency in heart failure.

Professor Anker serves as a councillor on the board of the European Society of Cardiology (ESC). He is also a member and past President of the board of the Heart Failure Association (HFA) of the ESC, and is the founding President of the International Society on Sarcopenia, Cachexia and Wasting Disorders. He is founding Editor-in-Chief of two journals: *ESC Heart Failure* and the *Journal of Cachexia, Sarcopenia and Muscle*. Professor Anker also serves on the editorial boards of four scientific journals, including the *European Heart Journal*, the *European Journal of Heart Failure* and the *International Journal of Cardiology*. He also serves as a member of a number of international clinical trial steering committees, data and safety monitoring boards and endpoint committees of clinical trials, for several of which he is the Chair. Professor Anker is the author of more than 500 original papers, reviews and editorials, with more than 29,000 citations.

Professor Anker will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [New data in iron trials – what does this mean for patients?](#)
- [Cardiology interactive breakout session](#)

[Back to contents](#)

Steering Committee Biographies



Christian Breymann

Christian Breymann is Professor of Obstetrics and Gynaecology at the University of Zurich, Switzerland. He received his clinical training at the Munich University of Technology, Rechts der Isar Hospital, Germany, and went on to train in gynaecology and obstetrics at the University of Zurich.

Professor Breymann's main areas of research are in haematological diseases in obstetrics, iron metabolism, recombinant erythropoietin in gynaecology and obstetrics, physiology of erythropoiesis in mother and foetus, and the diagnosis and treatment of anaemia. He serves as a Research Group Leader with Zentrum für Klinische Forschung (ZKF) (Centre for Clinical Research) in obstetrics research for foetomaternal haematology. Professor Breymann is a member of the Editorial Board of Transfusion Alternatives in Transfusion Medicine and of many societies, including the Swiss Obstetrics and Gynaecology Society and the Network on Advancements on Transfusion Alternatives.

Professor Breymann will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [New data in iron trials – what does this mean for patients?](#)
 - Pregnancy
- [Postpartum and heavy menstrual bleeding breakout session](#)

[Back to contents](#)

Steering Committee Biographies



Iain Macdougall

Iain Macdougall is Consultant Nephrologist and Professor of Clinical Nephrology at King's College London, United Kingdom. His subspecialty interest is in anaemia associated with chronic kidney disease, and he has published widely in the field. He is also the Research and Development Lead for the Renal Department at King's, and the South London Renal Comprehensive Local Research Networks (CLRN) lead for the National Institute for Health Research (NIHR) network.

With his research team, Professor Macdougall has led several pivotal multicentre clinical trials that have shaped the management of renal anaemia worldwide. As a member of the Kidney Disease Improving Global Outcomes (KDIGO) international work group, he was selected to create the latest clinical practice guideline for the management of anaemia in chronic kidney disease.

Professor Macdougall is a member of the American Society of Nephrology, the European Renal Association, the Renal Association, and the Royal Society of Medicine.

Professor Macdougall will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Introduction to iron metabolism and clinical picture of ID\(A\)](#)
- [New data in iron trials – what does this mean for patients?](#)
Chronic kidney disease
- [Optimal dosing and monitoring of IV iron therapy breakout session](#)
- [IV iron preparations and safety](#)

[Back to contents](#)

Faculty Biographies



Luis Bahamondes

Luis Bahamondes is Professor of Gynaecology in the Department of Obstetrics and Gynaecology, at the University of Campinas, São Paulo, Brazil. He was awarded his Medical Degree from the Federal University of Córdoba, Argentina, and subsequently his PhD degree from the University of Campinas.

His research interests focus on the clinical and molecular aspects of contraception and menstrual disorders, and he has conducted several clinical trials and authored numerous scientific papers on the subject of women's health. His other areas of research include the use of hormonal contraceptives for menstrual bleeding control and associated menstrual irregularities, the management of endometriosis and fibromyalgia, intrauterine contraception, and infertility.

Professor Bahamondes is a former Chairman of the Human Reproduction Unit at the University of Campinas. Professor Bahamondes is a former Chairman of the Human Reproduction Unit at the University of Campinas. He has authored several recommendations and reviews on the topics of menstrual abnormalities and abnormal uterine bleeding.

Professor Bahamondes will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Postpartum and heavy menstrual bleeding breakout session](#)

[Back to contents](#)

Faculty Biographies



Yves Beguin

Yves Beguin is Medical Director of the Laboratory of Cellular Therapy and Professor of Haematology and Head of the Haematology Division at the University of Liège, Belgium. He obtained his medical degree from the University of Liège in 1982 and his PhD in 1991. His research interests include haematopoietic stem cell transplantation and cellular therapy, iron metabolism, erythropoiesis, and factors governing the erythropoietic response to the use of erythropoietin in patients with cancer

Professor Beguin is a former President of the Belgian Haematological Society and Chairman of its Transplant Committee, and a former President of the National Marrow Donor Program in Belgium. He has served as a member of the National Blood Council, the American Society of Hematology Subcommittee on Iron and Heme, and has been actively involved with numerous other prestigious scientific societies. He has published over 300 articles in international peer-reviewed journals, and is the recipient of many awards

Professor Beguin will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Haematology and oncology breakout session](#)

[Back to contents](#)

Faculty Biographies



Patricia Blank

Patricia R Blank is Senior Research Scientist and University Lecturer at the Institute of Pharmaceutical Medicine (ECPM, University of Basel, Switzerland) and the Epidemiology, Biostatistics and Prevention Institute (EBPI, University of Zurich, Switzerland). She obtained her Masters degree in Human Biology and her PhD in Biology at the University of Zurich. In addition, she completed a Certificate of Advanced Studies in Pharmaceutical Medicine (Dipl. Pharm.med., University of Basel) and a Master of Public Health (MPH) at the Harvard School of Public Health in Boston, USA.

She has a wide experience in health economics and modelling of diagnostic and pharmaceutical interventions. Her main research interests are in personalised medicine in oncology, vaccines and vaccination behaviour (for influenza, pneumococcal and other infectious diseases) and in therapies for iron deficiency. In addition, she has been involved in epidemiological and health policy studies and collaborative work with international stakeholders and organisations, including the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO).

Dr Blank has published extensively in many peer-reviewed journals and has authored several book chapters.

Dr Blank will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Pharmacoeconomics of iron therapy breakout session](#)
- [Health economics and ID](#)

[Back to contents](#)

Faculty Biographies



Philippe Chassagne

Philippe Chassagne is Professor of Internal Medicine in Gerontology at the Geriatric Hospital in the Centre Hospitalier Universitaire, Rouen, France, where he is also actively involved, as a teaching professor, with the education and guidance of students, residents and general practitioners in internal medicine. In addition, he is a practising hospital consultant with extensive experience, having also managed an acute geriatric ward in the university hospital since 1990.

Following his medical degree, Professor Chassagne gained Masters degrees both in Pharmacology and in Statistics and Epidemiology, and he also holds a Clinical Exercise Specialist degree in Biology and Sports Medicine. His subsequent PhD focused on gerontology.

Professor Chassagne's current research focuses on functional digestive disorders in the older adult population, with a focus on faecal incontinence, constipation and gastric emptying. He also has related research interests in comprehensive geriatric assessment related to cardiology, oncology and nephrology, and has authored publications in the fields of iron deficiency and iron deficiency anaemia related to the elderly population. He is an advisory member of several societies, Chair of the National College of Geriatrics, Coordinator for North West Region Géraitrie DESC, and President of the French College of Geriatrics.

Professor Chassagne will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [ID in the elderly breakout session](#)

[Back to contents](#)

Faculty Biographies



Carlo Gaillard

Carlo Gaillard is Internist Nephrologist and Professor and Chair of Nephrology at the University Medical Centre, Groningen. Previously he was Internist Nephrologist at the VU University Medical Centre, Amsterdam, and the Meander Medical Centre, Amersfoort, the Netherlands, where he was also Director of Training in Internal Medicine.

He received his medical degree from the University of Utrecht Medical Center, Utrecht, the Netherlands, and was appointed Professor of Nephrology at the VU University in 2011. Professor Gaillard has a specific interest in renal physiology, and in cardiorenal and cardiometabolic interactions, including anemia and iron deficiency. Other research interests include blood pressure regulation and renal haemodynamics, fueled by his stay as a visiting Assistant Professor at the Department of Physiology (AC Guyton and JE Hall) at the University of Mississippi.

Professor Gaillard is Principal Investigator of the EPOCARES (Erythropoietin in the Cardiorenal Syndrome) study, and has received research funding from the European Renal Association and the American Heart Association. He has co-organized the Dutch Cardiorenal Meeting for many years, and is a member of various national and international advisory boards.

Professor Gaillard is a past Associate Editor of the Netherlands Journal of Medicine, and has served as an editorial board member or reviewer for a number of journals.

Professor Gaillard will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Cardiology/renal breakout session](#)

[Back to contents](#)

Faculty Biographies



Christoph Gasche

Christoph Gasche is Director, Christian Doppler Laboratory for Molecular Cancer Chemoprevention and Division of Gastroenterology & Hepatology, Department of Medicine 3, Medical University of Vienna, Austria.

Professor Gasche graduated in Medicine in 1989 and trained in Internal Medicine for six years and in Gastroenterology and Hepatology for a further three years at the University of Vienna, Austria. He also conducted research in inflammatory bowel diseases and mucosal immunology, before spending an extended sabbatical (1999–2001) at the University of California, San Diego, CA, USA, studying molecular aspects of inflammation-driven colorectal cancer and genetic instability.

His current laboratory-based work includes both basic research and clinical applications, primarily related to chronic intestinal inflammation and colorectal cancer. In regard to inflammatory bowel disorder, a longstanding research interest at the laboratory has been in iron therapy for anaemia and, more recently, in thrombocytosis.

Professor Gasche is the founder of *Loha for Life* – an Austrian-based competence centre for iron deficiency whose mission is to help transform science into daily clinical practice. He serves on several editorial boards and is an active or honorary member of many professional societies. He has authored over 100 peer-reviewed articles in his field of research, including 20 book chapters.

Professor Gasche will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Monitoring patients and maintenance therapy](#)
- [Optimal dosing and monitoring of IV iron therapy breakout session](#)

[Back to contents](#)

Faculty Biographies



Nicholas Kassebaum

Nicholas J Kassebaum is an Assistant Professor at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, WA, USA, where he works with the Global Burden of Disease (GBD) and Cost-Effectiveness research teams. He works in clinical practice as a staff anaesthesiologist, in attendance on the inpatient acute and chronic pain management services in the Department of Anesthesiology and Pain Medicine at Seattle Children's Hospital.

Professor Kassebaum earned a BA *cum laude* from Macalester College in St. Paul, MN, and also studied as an undergraduate at Cambridge University in the United Kingdom. He gained his medical degree from Vanderbilt University, Nashville, TN, did his residency in anaesthesiology at the University of Washington, and completed a fellowship in pediatric anaesthesiology at Seattle Children's Hospital.

He is currently researching the burden and effectiveness of interventions for specific conditions, and the potential role of expanded surgical and anaesthesia services in addressing unmet international need, as well as analyzing hospital data on surgical cost effectiveness in various healthcare settings around the world. Within GBD, he has a special interest in maternal and child health issues, including congenital diseases and haemoglobinopathies, anaemia, oral and dental health, as well as sexually transmitted infections.

His clinical interests are in regional anaesthesia, non-cardiac surgery for patients with congenital heart disease, multimodal pain therapy, and remote anaesthesia practice.

Dr Kassebaum will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Global burden of anaemia and ID\(A\)](#)
- [Haematology and oncology breakout session](#)

[Back to contents](#)

Faculty Biographies



Sigismond Lasocki

Sigismond Lasocki is Head of Department of Anaesthesiology and Critical Care at the University Hospital of Angers, France. Professor Lasocki works in clinical practice as a lead intensive care physician managing patients undergoing emergency surgery, and is also responsible for anaesthesiology procedures required in gastrointestinal, urological, endoscopic and ophthalmological interventions.

His clinical and research interests include patient blood management, the diagnosis and treatment of iron deficiency in patients undergoing surgery, regulation of iron metabolism of anaemia in critical care patients. He is currently leading a clinical trial in France which is investigating the potential role of hepcidin as a diagnostic marker of iron deficiency in critically ill patients (HEPCIDANE study).

Professor Lasocki has numerous peer-reviewed original and review articles relating to the prevalence, diagnosis and management of iron deficiency and anaemia during the perioperative period.

Professor Lasocki will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [ID in surgery breakout session](#)

[Back to contents](#)

Faculty Biographies



Jolanta Małyszko

Jolanta Małyszko is Head of the 2nd Department of Nephrology and Hypertension with Dialysis Unit, at the Medical University of Białystok, Poland, where she has been Professor since 2002. She obtained her medical degree with distinction from the Medical University of Białystok, before completing a PhD on haemostasis in chronic renal failure. She is a board-certified specialist in internal medicine (1995), nephrology (1998), clinical transplantation (2004), hypertension (2006) and diabetology (2010), in Poland. She has completed clinical training at several institutions throughout the world, including Rouen, France (1992), Heinrich Heine University, Dusseldorf, Germany, King's College, London, United Kingdom (2010), and Ichilov Hospital, Tel Aviv, Israel (2011).

Her research focus throughout her clinical and scientific career has been on nephrology and transplantation, and her main research interests are in iron metabolism and anaemia in chronic kidney disease (CKD), and cardiovascular complications in CKD. She is also a European Specialist in clinical hypertension. In addition to being a member of numerous professional societies, she is a Fellow of the American Society of Nephrology (FASN), and in 2013 was granted with the title of Distinguished Fellow of the European Renal Association (FERA).

Professor Małyszko has authored or co-authored over 300 original papers in peer-reviewed journals, over 100 review papers and 27 book chapters, and has served as a reviewer for several nephrological peer-reviewed journals.

Professor Małyszko will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Nephrology breakout session](#)

[Back to contents](#)

Faculty Biographies



Lorenzo Mantovani

Lorenzo G Mantovani is Associate Professor of Public Health at the University of Milano-Bicocca, Milan, Italy, where he works in the Department of Statistics and Quantitative Methods. He gained a degree in economics from Bocconi University in Milan, and a DSc in Epidemiology from Erasmus University in Rotterdam, the Netherlands.

His research interest are in pharmaco-economic analysis, outcomes research, health economics for developing countries, cost-utility analysis and healthcare management, particularly in relation to heart failure, hypertension and cardiology. He is currently researching the economic and epidemiological burden of diabetes mellitus, the cost-effectiveness of new drugs and treatment options for chronic hepatitis C patients, and the clinical and economic impact of exacerbations of chronic obstructive pulmonary disease in the population of northern Italy.

Dr Mantovani is also a pharmaco-economic advisor to the Italian Regional Health authorities, and has received several awards, including the International Society for Pharmacoeconomics and Outcomes Research Distinguished Service Award and the EFPIA Scientist of Tomorrow Award

Dr Mantovani will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Pharmacoeconomics of iron therapy breakout session](#)

[Back to contents](#)

Faculty Biographies



Laurent Peyrin-Biroulet

Laurent Peyrin-Biroulet is Professor of Medicine and Head of the Inflammatory Bowel Disease (IBD) Unit (Inserm U954) at the Nancy University Hospital in France. After gaining his medical degree and PhD, he undertook a postdoctoral fellowship at the IBD Centre in Lille in 2007, before taking a research position at the Mayo Clinic in Rochester, MN, USA.

He was the recipient of a Rising Star award in 2008 from the United European Gastroenterology Federation (UEGF), and is a member of several societies, including the ClinCom committee of the European Crohn's & Colitis Organization (ECCO). He is Vice-President of GETAID (Groupe d'Étude Thérapeutique des Affections Inflammatoires du Tube Digestif); Vice-President of the French Association of IBD patients (AFA); Chair of the IBD Committee of the French Society of Digestive Endoscopy (SFED); and Chair of the Clinical Trials Task Force at the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD).

Professor Peyrin-Biroulet has authored more than 250 peer-reviewed articles in journals including *The Lancet*, *Gastroenterology*, *Proceedings of the National Academy of Sciences* and *Gut*, as well as over 200 other published articles. He is an associate editor of *Digestive & Liver Disease*, and a member of the editorial boards of *Alimentary Pharmacology & Therapeutics* and the *Journal of Crohn's and Colitis*, and serves as a reviewer for several international journals, including *The Lancet*, *Gastroenterology* and *Gut*. He joined the editorial team of the Cochrane Inflammatory Bowel Diseases and Functional Bowel Disorders (IBD/FBD) Review Group in 2014.

Professor Peyrin-Biroulet will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Gastroenterology breakout session](#)

[Back to contents](#)

Faculty Biographies



Piotr Ponikowski

Piotr Ponikowski is Professor of Cardiology and Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Centre for Heart Diseases at the 4th Military Hospital, Wroclaw, Poland.

He is a past-President of the Heart Failure Association of the European Society of Cardiology (ESC) and a member of the ESC Board. He has been involved in the development of several ESC guidelines, including the ESC

Guidelines on the Diagnosis and Treatment of Acute and Chronic Heart Failure.

Professor Ponikowski's principal research interests include heart failure (HF), coronary artery disease and cardiac arrhythmias, and he has participated in numerous research projects, including studies on the benefits of physical rehabilitation in patients with chronic HF; the assessment of metabolic derangements in HF (with special interest in iron deficiency); and the evaluation of reflex control in the cardiorespiratory system in order to optimize assessment and management of patients with HF. He has been the principal investigator in numerous clinical trials, and has served on several international steering committees, endpoint committees and advisory boards. In addition, Professor Ponikowski acts as a reviewer for several journals and is a member of numerous editorial boards. He has co-authored over 300 publications, and more than 10,000 citations of his work have appeared in the international literature.

Professor Ponikowski will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [New data in iron trials – what does this mean for patients?](#)
 - Chronic heart failure (CHF)
- [Cardiology/renal breakout session](#)

[Back to contents](#)

Faculty Biographies



Toby Richards

Mr Toby Richards is an academic Senior Lecturer at the University College London and practising Vascular Surgeon at University College Hospital, United Kingdom (UK). He has a strong interest in Patient Blood Management. Working with the UK Department of Health Working Group of NHS Blood and Transplant and the British Blood Transfusion Society, the UK has developed 'Patient Blood Management – The future of Transfusion Medicine'. Endorsed by Sir Bruce Keogh, Patient Blood Management is now an internationally recognised program of quality improvement to be adopted in the NHS in 2015 with CQUIN targets proposed for all NHS trusts.

Mr Richards has an ongoing 'iron first' approach to treat anaemia before and after operation. He is currently running a NIHR HTA multicentre randomised clinical trial to explore the effect of intravenous iron to prevent transfusion (PREVENTT) in patients undergoing major surgery. Five-hundred patients in 30 centres will be randomised to preoperative intravenous iron or placebo in a double blind manner before major surgery. The aim is to assess impact of this intervention on transfusion and outcomes following operation.

Mr Richards has numerous publications on perioperative anaemia management as well as broad reaching impact publications with the UK Department of Health circular on Patient Blood Management and British Society for Haematology guidelines.

Mr. Richards will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [ID in surgery breakout session](#)

[Back to contents](#)

Faculty Biographies



Austin Stack

Austin Stack is Foundation Chair of Medicine at the Graduate Entry Medical School (GEMS) and Consultant Nephrologist at University Hospital Limerick, Ireland. He is the Director of the Health Research Institute (HRI) at the University of Limerick. His research interests focus on the complications and treatment strategies for chronic kidney disease (CKD) and end-stage renal disease; determinants and outcomes of acute kidney injury; cardiovascular disease and cardiovascular risk assessment; clinical impact of gout and hyperuricaemia; risk prediction models; the role of iron deficiency and anaemia in CKD and cardiovascular disease; and the application of IT communications systems in clinical and epidemiological research.

Professor Stack is leading an initiative to establish Ireland's first National Surveillance System for Kidney Disease. Professor Stack is Principal Investigator for several large-scale observational studies, including two Health Research Board (HRB)-funded studies to assess the burden and progression of CKD and Acute Kidney Injury (AKI) in the Irish health system. His research has been supported by the National Institutes of Health (NIH), American Heart Association (AHA), National Kidney Foundation (NKF), Health Research Board (HRB) and industry. In Ireland, Professor Stack is the Clinical Director of the National Renal IT Project which aims to establish a state-wide renal information network for patients with kidney disease in Ireland and support a renal registry.

Professor Stack's clinical interests include the care of patients with kidney disease and related conditions, CKD, AKI, dialysis, haemodialysis, peritoneal dialysis, hypertension and kidney transplantation.

Professor Stack will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Nephrology breakout session](#)

[Back to contents](#)

Faculty Biographies



Dirk van Veldhuisen

Dirk van Veldhuisen is Professor and Chairman of Cardiology at the University Medical Centre Groningen, the Netherlands, a post that he took up in 2001. After completing his training in Internal Medicine and Cardiology in Rotterdam and Groningen, he completed research fellowships in Switzerland, South Africa, and USA. He has been a certified cardiologist since 1991, receiving his PhD in 1993, and has been the recipient of numerous grants from the Netherlands Heart Foundation, as well as being an Established Investigator of the Foundation since 1997.

He has a long-standing interest in clinical and experimental heart failure, with particular interests in the treatment of heart failure, including both pharmacological and non-pharmacological (device) interventions, neurohormonal activation, arrhythmias, and renal dysfunction/anaemia.

He has supervised 50 PhD candidates in field of research over the last 15 years. Professor van Veldhuisen has been a national coordinator or steering committee member for over 30 trials investigating heart failure, as well as a principal investigator in six of them, including EFFECT-HF. He is a member of the Working Group of Heart Failure of the Netherlands Society of Cardiology, and served as its Chairman from 1997 to 2002. He is also a Member of the Heart Failure Association of the European Society of Cardiology (ESC).

Professor van Veldhuisen is Editor-in-Chief of the *European Journal of Heart Failure* and serves as a member on the editorial boards of several other journals. He is the coauthor of more than 600 publications.

Professor van Veldhuisen will be presenting/moderating the following sessions at the 2015 European Iron Academy:

- [Cardiology breakout session](#)

[Back to contents](#)

Plenary session: Day 1

Welcome and introduction

A welcome from [Dr. Keshav](#) and [Prof. Cacoub](#) to the European Iron Academy 2015 who will introduce the steering committee and faculty speakers, and give a brief overview of the meeting.

Plenary session: Day 1

Global burden of anaemia and ID(A)

In this session, Dr Kassebaum will provide an introduction to iron metabolism and give an overview of ID/IDA in the clinical setting.

Learning objectives

Upon completion of this session, participants should be able to:

1. Describe the global prevalence of, and risk factors for ID/IDA, in terms of nutritional causes, underlying medical conditions and socio-economic aspects
2. Describe main symptoms associated with ID and its main diagnostic biomarkers
3. Appreciate the clinical, social and economic consequences of ID/IDA

[Nicholas Kassebaum biography](#)

[Back to contents](#)

Plenary session: Day 1

Physical symptoms and diagnosis

In this session, Professor Cacoub will address the physical symptoms and diagnosis of iron deficiency in different disease areas.

Learning objectives

Upon completion of this session, participants should be able to:

1. Describe the main clinical features of absolute and functional ID in different disease settings, including oncology, gastroenterology, cardiology and women's health
2. Demonstrate a knowledge of the key diagnostic techniques for the detection of ID/IDA
3. Demonstrate awareness about the underdiagnosis and undertreatment of ID/IDA, and the importance of addressing this problem

[Patrice Cacoub biography](#)

[Back to contents](#)

Plenary session: Day 1

Introduction to iron metabolism and clinical picture of ID/IDA

In this session, Professor Iain Macdougall will provide an introduction to iron metabolism and give an overview of the pathology of ID/IDA in the clinical setting.

Learning objectives

Upon completion of this session, participants should be able to:

1. Describe the physiological role of iron in the human body
2. Understand the mechanisms of iron homeostasis and metabolism
3. Describe the difference between absolute and functional ID, with a focus on the role of inflammation
4. Understand the pathophysiology of ID/IDA and latest research in this area

[Iain Macdougall biography](#)

[Back to contents](#)

Plenary session: Day 1

New data in iron trials – what does this mean for patients?

Learning objectives

In this session, Prof. Anker, Prof. Breymann, Prof. Ponikowski and Prof. Macdougall will review the latest clinical trial data relating to the treatment of ID/IDA with parenteral iron formulations in pregnancy, chronic heart failure and chronic kidney disease.

Upon completion of this session, participants should be able to:

1. Demonstrate an awareness of the latest clinical developments in treatment of ID
2. Describe key data from recent clinical trials of treatment with parenteral iron formulations in pregnancy, chronic heart failure (CHF) and chronic kidney disease (CKD)

[Stefan Anker biography](#)

[Christian Breymann biography](#)

[Piotr Ponikowski biography](#)

[Iain Macdougall biography](#)

[Back to contents](#)

Breakout sessions: Day 1 and Day 2

Cardiology

In this interactive breakout session, Prof. Anker and Prof. Veldhuisen will address the implications of ID/IDA in cardiovascular disease.

Learning objectives

Upon completion of this session, participants should be able to:

1. Understand the clinical significance of ID in patients with cardiovascular disease, particularly in CHF
2. Demonstrate an awareness about the advantages and limitations of different diagnostic approaches for ID in cardiology
3. Demonstrate an awareness about the benefit of iron therapy for improving outcomes of CHF patients with ID/IDA

[Stefan Anker biography](#)

[Dirk J. Van Veldhuisen biography](#)

[Back to contents](#)

Breakout sessions: Day 1 and Day 2

Gastroenterology

In this interactive breakout session, Dr Keshav and Prof. Peyrin-Biroulet discuss the diagnosis and management of ID/IDA in patients with gastrointestinal disorders.

Learning objectives

Upon completion of this session, participants should be able to:

1. List the three major causes of ID in gastrointestinal (GI) disorders (bleeding, inflammation and malabsorption)
2. Demonstrate an awareness of the impact of ID/IDA on QoL and outcomes in patients with GI disorders including inflammatory bowel disease (IBD), GI bleeding, coeliac disease and obesity, and those undergoing bariatric surgery
3. Outline the key principles of treatment for ID/IDA in GI disorders, with an awareness of the benefits and disadvantages of the treatment options available

[Satish Keshav biography](#)

[Laurent Peyrin-Biroulet biography](#)

=====

Breakout sessions: Day 1 and Day 2

ID in Surgery

Learning objectives

Upon completion of this session, participants should be able to:

1. Understand the importance of patient blood management (PBM) and pre-operative management of ID/IDA
2. Describe the challenges of ID/IDA management in different types of surgery, including bariatric, cardiac and gynaecological surgery

[Sigismond Lasocki biography](#)

[Toby Richards biography](#)

[Back to contents](#)

Breakout sessions: Day 1 and Day 2

Nephrology

In this interactive breakout session, Prof. Małyszko and Prof. Stack will describe the pathogenesis of ID/IDA, the challenges associated with diagnosis and treatment guidelines for ID/IDA in relation to chronic kidney disease (CKD)

Learning objectives

Upon completion of this session, participants should be able to:

1. Understand the burden and pathogenesis of ID/IDA in CKD, as well as its clinical outcomes and impact on patient quality of life (QoL)
2. Describe the specific challenges of ID diagnosis in CKD and identify appropriate markers for identifying ID in CKD
3. Outline diagnostic and treatment guidelines for ID/IDA in CKD, with an awareness of the benefits/disadvantages of the different treatment options

[Jolanta Małyszko biography](#)

[Austin Stack biography](#)

[Back to contents](#)

Breakout sessions: Day 1 and Day 2

Pharmacoeconomics of iron therapy

In this interactive breakout session, Dr Mantovani and Dr Blank will describe the cost of ID to society and the relative value of available ID treatments.

Learning objectives

Upon completion of this session, participants should be able to:

1. Demonstrate an awareness of the societal cost of ID
2. Understand the costs and benefits – and disadvantages – associated with the available ID treatment options
3. Engage in a discussion with hospital pharmacists about the value of different treatment options for ID/IDA, with reference to specific groups of patients

[Lorenzo Mantovani biography](#)

[Patricia Blank biography](#)

[Back to contents](#)

Breakout sessions: Day 1 and Day 2

Cardiology/renal

In this interactive breakout session, Prof. Gaillard and Prof. Ponikowski will discuss the effects of IDA in relation to cardio-renal syndrome.

Learning objectives

Upon completion of this session, participants should be able to:

1. Understand the link between heart failure, kidney failure and anaemia, and the vicious cycle of deterioration that they cause in patients with cardio-renal syndrome
2. Demonstrate an awareness of the clinical data supporting the use of iron-replacement therapy in CHF and CKD
3. Describe the optimal diagnostic and treatment methods for patients with CHF and CKD

[Carlo Gaillard biography](#)

[Piotr Ponikowski biography](#)

[Back to contents](#)

Breakout sessions: Day 1 and Day 2

Haematology and oncology

In this interactive breakout session, Dr Kassebaum and Prof. Beguin will discuss the diagnosis and management of ID/IDA in patients with cancer.

Learning objectives

Upon completion of this session, participants should be able to:

1. Explain the effects of ID/IDA in cancer patients in terms of reduced QoL, morbidity and mortality
2. Demonstrate an awareness of the types of cancer in which ID/IDA pose a particular problem
3. Describe management options for ID in cancer patients, including breast cancer and GI tumours

[Nicholas Kassebaum biography](#)

[Yves Beguin biography](#)

[Back to contents](#)

Breakout sessions: Day 1 and Day 2

ID in the elderly

In this interactive breakout session, Prof. Cacoub and Prof. Chassagne discuss ID/IDA in the elderly.

Learning objectives

Upon completion of this session, participants should be able to:

1. Understand the impact of ID/IDA on elderly people
2. Describe the clinical features of ID/IDA in the elderly, including its effect on physical function, risk of falls, cognitive impairment and mortality
3. Describe the challenges associated with diagnosing ID/IDA in elderly patients and the importance of diagnosing ID before IDA develops

[Patrice Cacoub biography](#)

[Philippe Chassagne biography](#)

=====

Breakout sessions: Day 1 and Day 2

Optimal dosing and monitoring of IV iron therapy

In this interactive breakout session, Prof. Macdougall and Prof. Gasche discuss optimal dosing of IV iron therapy and monitoring of treatment in different types of patients.

Learning objectives

Upon completion of this session, participants should be able to:

1. Describe the key safety data on the use of IV iron from clinical trials
2. Demonstrate an awareness of the key principles of monitoring iron parameters in patients receiving IV iron therapy

[Iain Macdougall biography](#)

[Christoph Gasche biography](#)

[Back to contents](#)

Breakout sessions: Day 1 and Day 2

Postpartum and heavy menstrual bleeding

In this interactive breakout session, Prof. Breymann and Prof. Bahamondes will discuss ID/IDA in relation to women's health, with a focus on heavy menstrual bleeding, pregnancy and postpartum.

Learning objectives

Upon completion of this session, participants should be able to:

1. Understand the pathogenesis and burden of ID/IDA in women's health: pregnancy, postpartum and heavy menstrual bleeding patients
2. Describe the diagnostic signs and symptoms of ID/IDA in a variety of patient types, including pregnancy, post-partum and heavy menstrual bleeding patients
3. Outline the guidelines of ID management in women's health

[Christian Breymann biography](#)

[Luis Bahamondes biography](#)

[Back to contents](#)

Plenary session (Day 2)

Health economics and ID

In this session, Dr. Blank will describe the impact of ID from a health-economics perspective.

Learning objectives

Upon completion of this session, participants should be able to:

1. Understand the health-economic impact of ID in different patient populations
2. Demonstrate awareness about the available cost-effectiveness data for the treatment of ID

[Patricia Blank biography](#)

Plenary session (Day 2)

Monitoring patients and maintenance therapy

In this session, Prof. Gasche will discuss the principles of monitoring patients with ID/IDA being treated with IV iron therapy, with focus on patients with gastrointestinal disorders.

Learning objectives

Upon completion of this session, participants should be able to:

1. Describe the rationale for iron maintenance therapy in patients with ID
2. Demonstrate an understanding of the key principles of monitoring iron parameters in patients receiving maintenance intravenous (IV) therapy
3. Discuss the available clinical trial data for IV iron maintenance therapy in different patient populations

[Christoph Gasche biography](#)

[Back to contents](#)

Plenary session (Day 2)

IV iron preparations and safety

In this session, Prof. Macdougall will discuss the safety of using IV iron therapy for the treatment of patients with ID/IDA.

Learning objectives

Upon completion of this session, participants should be able to:

1. Summarise the potential safety issues with currently available IV iron therapies
2. Discuss the key safety data from clinical trials on the use of IV iron
3. Understand how best to monitor adverse events in patients undergoing treatment with IV iron

[Iain Macdougall biography](#)

=====

Plenary session (Day 2)

Review of meeting highlights and looking to the future

In this session, Dr Keshav will review highlights of the meeting and discuss future directions in the field of ID/IDA.

[Dr Satish Keshav biography](#)

=====

Plenary session (Day 2)

Meeting summary and close

In this closing session, Prof. Cacoub will summarize the key points of the meeting from his own perspective.

[Patrice Cacoub biography](#)

[Back to contents](#)